Loading
Esophageal Squamous Cell Carcinoma / Immune Checkpoint Inhibitors / Esophageal Neoplasms · Journal article
Cancer Biology & Therapy · March 11, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines the compositional characteristics of the tumor immune microenvironment (TIME) in esophageal squamous cell carcinoma (ESCC) and discusses immunological predictive models. It highlights the role of tumor-infiltrating lymphocytes, immune checkpoints, and the heterogeneity of TIME in determining immunotherapy efficacy and prognosis, aiming to provide a theoretical basis for improving immunotherapy outcomes.
Journal article. Patients with esophageal squamous cell carcinoma (ESCC), particularly those receiving immunotherapy.
High levels of tumor-infiltrating lymphocytes (TILs) are related to better prognosis in ESCC patients CD8+ T cell infiltration density correlates with overall survival in ESCC patients Only a small percentage of patients show persistent clinical response to immune checkpoint inhibitors
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that TIME heterogeneity contributes to variable immunotherapy response in ESCC and that understanding immune cell composition may inform treatment selection. The review underscores the need for validated predictive biomarkers beyond PD-L1 to identify patients likely to benefit from immune checkpoint inhibitors.
This is a narrative review synthesizing existing literature on immune microenvironment characteristics and predictive models in ESCC without presenting original data or comparative efficacy evidence.
As stated by the source record.
Clinicians should recognize that TIME heterogeneity contributes to variable immunotherapy response in ESCC and that understanding immune cell composition may inform treatment selection. The review underscores the need for validated predictive biomarkers beyond PD-L1 to identify patients likely to benefit from immune checkpoint inhibitors.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Esophageal cancer is one of the most prevalent malignant tumors of the digestive tract, with esophageal squamous cell carcinoma (ESCC) as its main histological type. In recent years, immunotherapeutic regimens centered on immune checkpoint inhibitors (ICIs) have achieved remarkable efficacy in patients with advanced ESCC. However, due to the heterogeneity of the tumor immune microenvironment (TIME), the degree of clinical benefit varies among patients. This heterogeneity not only affects the biological behavior of tumors but also determines the efficacy and prognosis of immunotherapy. Therefore, exploring the interactions between tumor cells and diverse immunological components inside the TIME in ESCC, as well as how to use ICIs to reshape the TIME, may bring new therapeutic opportunities for ESCC patients. This review looks at the important aspects of TIME and immunological prediction models and explores potential therapeutic strategies targeting both, providing a theoretical basis for improving immunotherapy outcomes in ESCC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.